HAO Capital is a China-focused Private Equity firm with offices in Beijing, Hong Kong and Kunming. Founded in 2006, the firm manages total assets in excess of US$600 million across four funds:

• HAO Fund I 
• HAO Fund II 
• HAO Auxiliary Fund 
• HAO RMB Fund 

Our skilled and diverse team has wide ranging experience across many fields including investment, legal, capital markets, cross-border M&A and operational management.

• Buchang announces dividend for FY2018 August 15, 2019
• TCL Healthcare enters the High Dose Rate Brachytherapy solutions market in China August 1, 2019
• AMS receives approval to start clinical trials for 18F-NaF July 17, 2019
• Daijia helped the 2nd Hospital of Jilin University pass the “Interconnected Hospital Information Test” June 21, 2019
• Buchang announces dividend for 2017 June 30, 2018
• Daijia completes Series A-2 fundraising round June 30, 2017
• Buchang announces dividend for 2016 May 30, 2017
• AMS acquired by A-share listed Dongcheng May 25, 2017